Canada in the face of the 2009 H1N1 pandemic

Influenza and other Respiratory Viruses

Volumn 5, Issue 2, 2011, Pages 83-88

  Moghadas, Seyed M ^a   Pizzi, Nick J ^a   Wu, Jianhong ^b   Tamblyn, Susan E ^c   Fisman, David N ^d  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^b YORK UNIVERSITY   (Canada)

^c Public Health Consultant   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Influenza H1N1 pandemic; Intervention strategies; Modelling; Policy decision making

Indexed keywords

INFLUENZA VACCINE; ZANAMIVIR;

ANTIVIRAL THERAPY; ARTICLE; CANADA; EMERGENCY; HEALTH CARE POLICY; HUMAN; INFLUENZA A (H1N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; MEDICAL DECISION MAKING; PANDEMIC; PRIORITY JOURNAL; PUBLIC HEALTH; RESOURCE ALLOCATION; WORKSHOP;

ANTIVIRAL AGENTS; CANADA; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; PANDEMICS; PUBLIC HEALTH; VACCINATION;

EID: 79751494197     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/j.1750-2659.2010.00184.x     Document Type: Article

References (40)

1. Pan-InfORM Workshop. The First Influenza Pandemic of the 21st Century: Canada's Response, Lessons Learned, and Challenges Ahead. Available at
2. Pan-InfORM, Pandemic Influenza Outbreak Research Modelling Team. Available at
3. Smetanin P., Stiff D., Kumar A. et al. Potential intensive care unit ventilator demand/capacity mismatch due to novel swine-origin H1N1 in Canada. Can J Infect Dis Med Microbiol 2009; 20:e115-e123.
4. Kumar A. Description of clinical management and challenges experienced in Winnipeg ICUs. Available at (Accessed 25 May 2010).
5. Kumar A., Zarychanski R., Pinto R. et al., for the Canadian Critical Care Trials Group H1N1 Collaborative. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA 2009; 302: 1872-1879.
6. Zarychanski R., Stuart T.L., Kumar A. et al. Correlates of severe disease in patients with 2009 pandemic influenza (H1N1) virus infection. CMAJ 2010; 182:257-264.
7. Canadian Communicable Disease Report, Public Health Agency of Canada. Available at (Accessed 27 August 2010).
8. Campbell A., Rodin R., Kropp R. et al. Risk of severe outcomes among patients admitted to hospital with pandemic (H1N1) influenza. CMAJ 2010; 182:349-355.
9. Public Health Agency of Canada. Canadian Pandemic Influenza Plan for the Health Sector, 2006. Available at (Accessed 5 August 2010).
10. Public Health Agency of Canada. Guidance on H1N1 Flu Vaccine Sequencing, 2009-09-16. Available at (Accessed 5 August 2010).
11. Public Health Agency of Canada. Pandemic Vaccine Prioritization Framework 2009. Appendix to Annex D: Preparing for the Pandemic Vaccine Response to the Canadian Pandemic Influenza Plan for the Health Sector (CPIP) 2006. Available at (Accessed 5 August 2010).
12. Public Health Agency of Canada. Guidance for Remote and Isolated (RI) Communities in the context of the pandemic (H1N1) 2009 outbreak. 2009. Available at (Accessed 5 August 2010).
13. Public Health Agency of Canada. Clinical Guidelines, 2009. Available at (Accessed 5 August 2010).
14. Health Canada. A Statistical Profile on the Health of First Nations in Canada. Ottawa, Ontario: Health Canada, 2009. Report No.: HC Pub: 3555. Available at (Accessed 25 May 2010).
15. Tuite A.R., Greer A.L., Whelan M. et al. Estimated epidemiologic parameters and morbidity associated with pandemic H1N1 influenza. CMAJ 2010; 182:131-136.
16. Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza, Bautista E., Chotpitayasunondh T., Gao Z. et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 2010; 362: 1708-1719.
17. Public Health Agency of Canada. Annex E: the use of antiviral drugs during a pandemic. Available at (Accessed 25 May 2010).
18. Public Health Agency of Canada. Clinical recommendations for patients presenting with respiratory symptoms during the 2009-2010 influenza season. Available at (Accessed 5 August 2010).
19. Hansen E., Day T., Arino J. et al. Strategies for use of oseltamivir and zanamivir during pandemic outbreaks. Can J Infect Dis Med Microbiol 2010; 21:e28-e63.
20. Tuite A., Fisman D.N., Kwong J.C. et al. Optimal pandemic influenza vaccine allocation strategies for the Canadian population. PLoS ONE 2010; 5:e10520.
21. Centers for Disease Control. 2009 H1N1 influenza school-located vaccination (SLV): information for planners. Available at (Accessed 25 May 2010).
22. Halloran M.E., Longini I.M. Jr. Community studies for vaccinating schoolchildren against influenza. Science 2006; 311:615-616.
23. Basta N.E., Chao D.L., Halloran M.E. et al. Strategies for pandemic and seasonal influenza vaccination of schoolchildren in the United States. Am J Epidemiol 2009; 170:679-686.
24. Basta N.E., Halloran M.E., Matrajt L. et al. Estimating influenza vaccine efficacy from challenge and community-based study data. Am J Epidemiol 2008; 168:1343-1352.
25. Longini I.M. Jr, Halloran M.E.. Strategy for distribution of influenza vaccine to high-risk groups and children. Am J Epidemiol 2005; 161:303-306.
26. Sander B., Bauch C., Fisman D.N. et al. Is a mass immunization program for pandemic (H1N1) 2009 good value for money? Early evidence from the Canadian experience. Vaccine 2010; 28(38): 6210-6220.
27. Tuite A., Fisman D.N., Kwong J.C. et al. Seasonal influenza vaccine allocation in the Canadian population during a pandemic. PLoS Curr: Influenza 2009; RRN1143.
28. Gojovic M.Z., Sander B., Fisman D.N. et al. Modelling mitigation strategies for pandemic (H1N1) 2009. CMAJ 2009; 181:673-680.
29. Greenbaum J.A., Kotturi M.F., Kim Y. et al. Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population. Proc Natl Acad Sci USA 2009; 106:20365-20370.
30. Fisman D.N., Savage R., Gubbay J. et al. Older age and a reduced likelihood of 2009 H1N1 virus infection. N Engl J Med 2009; 361:2000-2001.
31. Public Health Agency of Canada. Guidance for the Management of Pandemic (H1N1) 2009 Outbreaks in Closed Facilities. Available at (Accessed 25 May 2010).
32. Germann T.C., Kadau K., Longini I.M. Jr et al. Mitigation strategies for pandemic influenza in the United States. Proc Natl Acad Sci USA 2006; 103:5935-5940.
33. Tracht S.M., Del Valle S.Y., Hyman J.M.. Mathematical modeling of the effectiveness of facemasks in reducing the spread of novel influenza A (H1N1). PLoS ONE 2010; 5:e9018.
34. Cauchemez S., Valleron A.J., Boëlle P.Y. et al. Estimating the impact of school closure on influenza transmission from Sentinel data. Nature 2008; 452:750-754.
35. Miller J.C., Danon L., O'Hagan J.J. et al. Student behavior during a school closure caused by pandemic influenza A/H1N1. PLoS ONE 2010; 5: e10425.
36. Sander B., Nizam A., Garrison L.P. Jr et al. Economic evaluation of influenza pandemic mitigation strategies in the United States using a stochastic microsimulation transmission model. Value Health 2009; 12:226-233.
37. Public Health Agency of Canada. Individual and community based measures to help prevent transmission of influenza-like-illness (ILI), including the pandemic influenza (H1N1) 2009 virus in the community. Available at (Accessed 25 May 2010).
38. Moghadas S.M., Pizzi N.J., Wu J. et al. Managing public health crises: the role of models in pandemic preparedness. Influenza Other Respi Viruses 2009; 3:75-79.
39. Brauer F., Wu J. Modeling SARS, West Nile virus, pandemic influenza and other emerging infectious diseases: a Canadian team's adventure, in Modeling and Dynamics of Infectious Diseases. Contemp. Appl. Math. Series, Vol. 11. Beijing and World Scientific, Singapore: Higher Ed. Press, 2009; 36-63.
40. Moghadas S.M., Day T., Bauch C. et al. Modelling of pandemic influenza: a guide for the perplexed. CMAJ 2009; 181:171-173.